NantHealth (DB:NEL0) - Hisse Senedi Fiyatı, Haberler ve Analizler

NEL0 Stoklara Genel Bakış

Operates as a healthcare IT company in the United States, Canada, and the United Kingdom.

NEL0 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Risk Analizi

Negatif hissedar öz sermayesi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €13M )

NantHealth, Inc. Rakipler

MeVis Medical Solutions

XTRA:M3V

€44.4m

DocCheck

XTRA:AJ91

€46.4m

CompuGroup Medical SE KGaA

XTRA:COP

€698.9m

Nexus

XTRA:NXU

€838.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti NantHealth
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.26
52 Haftanın En Yüksek Seviyesi	US$5.17
52 Haftanın En Düşük Seviyesi	US$0.20
Beta	1.64
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-93.60%
33 Yıllık Değişim	-99.06%
5 Yıllık Değişim	-98.24%
Halka arzdan bu yana değişim	-99.86%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	NEL0	DE Healthcare Services	DE Pazar
7D	0%	-3.3%	-2.2%
1Y	-93.6%	-42.9%	13.3%

Getiri vs. Endüstri: NEL0 geçen yıl % -42.9 oranında getiri sağlayan German Healthcare Services sektörünün gerisinde kaldı.

Getiri vs Piyasa: NEL0 geçen yıl % 13.3 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is NEL0's price volatile compared to industry and market?
NEL0 volatility
NEL0 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	5.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: NEL0 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: NEL0 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2010	373	Rao Naseem	nanthealth.com

NantHealth, Inc. Temel Bilgiler Özeti

NantHealth'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NEL0 temel i̇stati̇sti̇kler
Piyasa değeri	€11.54m
Kazançlar(TTM)	-€63.09m
Gelir(TTM)	€62.54m

0.2x

P/S Oranı

-0.2x

F/K Oranı

NEL0 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NEL0 gelir tablosu (TTM)
Gelir	US$68.44m
Gelir Maliyeti	US$23.74m
Brüt Kâr	US$44.69m
Diğer Giderler	US$113.74m
Kazançlar	-US$69.04m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.51
Brüt Marj	65.31%
Net Kâr Marjı	-100.89%
Borç/Özkaynak Oranı	-111.3%

NEL0 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

NEL0 Stoklara Genel Bakış

Ödüller

Risk Analizi

NantHealth, Inc. Rakipler

XTRA:M3V

€44.4m

XTRA:AJ91

€46.4m

XTRA:COP

€698.9m

XTRA:NXU

€838.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.14 loss in 1Q 2021)

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought €4.2m worth of stock

Founder recently bought €4.2m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Chief Operating Officer recently sold €249k worth of stock

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue misses expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €3.88

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: €3.41

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Revenue beats expectations

Third quarter 2020 earnings released: US$0.099 loss per share

New 90-day low: €1.75

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low - €2.23

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında